Market Research Logo

Grindeks (GRD1R) - Financial and Strategic SWOT Analysis Review

Grindeks (GRD1R) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Grindeks focuses on the research, development, manufacture and marketing of novel pharmaceuticals, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and cancer therapeutic categories. The company provides final dosage form pharmaceutical products ranging from solid form products, solution for injections to syrups and ointments. Grindeks also provides regulatory, analytical and final dosage form contract manufacturing services to pharmaceutical companies. Through subsidiaries and representative offices, the company markets its products in the European (EU) countries, the US, Canada, Russia and other CIS countries, Japan and Vietnam. Grindeks operates subsidiary companies in Latvia, Estonia, Russia and Slovakia and is headquartered in Riga, Latvia.

Grindeks Key Recent Developments

May 31,2018: On “Grindeks” results in the first three months of 2018
May 07,2018: Turnover of “Grindeks” reaches 132.4 million euro in 2017; profit – 10.0 million euro
Feb 28,2018: Turnover of Grindeks reaches 132.4 million euro in 2017; profit – 10.3 million euro
Jan 09,2018: Juris Bundulis re-elected as the Chairman of the Board; Ph.D. Juris Hmelnickis to become a Board Member of JSC Grindeks
Nov 27,2017: On Grindeks results in the first nine months of 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Grindeks - Key Facts
Grindeks - Key Employees
Grindeks - Key Employee Biographies
Grindeks - Major Products and Services
Grindeks - History
Grindeks - Company Statement
Grindeks - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Grindeks - Business Description
Grindeks - Corporate Strategy
Grindeks - SWOT Analysis
SWOT Analysis - Overview
Grindeks - Strengths
Grindeks - Weaknesses
Grindeks - Opportunities
Grindeks - Threats
Grindeks - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Grindeks, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Grindeks, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 31, 2018: On “Grindeks” results in the first three months of 2018
May 07, 2018: Turnover of “Grindeks” reaches 132.4 million euro in 2017; profit – 10.0 million euro
Feb 28, 2018: Turnover of Grindeks reaches 132.4 million euro in 2017; profit – 10.3 million euro
Jan 09, 2018: Juris Bundulis re-elected as the Chairman of the Board; Ph.D. Juris Hmelnickis to become a Board Member of JSC Grindeks
Nov 27, 2017: On Grindeks results in the first nine months of 2017
Aug 28, 2017: Grindeks results in the first half-year of 2017
May 29, 2017: On “Grindeks” results in the first three months of 2017
Mar 01, 2017: Grindeks Announces the Board Change
Mar 01, 2017: Grindeks Announces the Board Change
Feb 28, 2017: Grindeks Announces results in 2016
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Grindeks, Key Facts
Grindeks, Key Employees
Grindeks, Key Employee Biographies
Grindeks, Major Products and Services
Grindeks, History
Grindeks, Subsidiaries
Grindeks, Key Competitors
Grindeks, Ratios based on current share price
Grindeks, Annual Ratios
Grindeks, Annual Ratios (Cont...1)
Grindeks, Annual Ratios (Cont...2)
Grindeks, Interim Ratios
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Grindeks, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Grindeks, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Grindeks, Performance Chart (2013 - 2017)
Grindeks, Ratio Charts
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Grindeks, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report